Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 4: 531 - 536

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.04.015

Review

Research progress in the treatment of interstitial lung disease related to polymyositis/dermatomyositis

  • ZHENG Xiaofeng ,
  • XU Ling
Expand
  • Department of Pulmonary and Critical Care Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
XU Ling, E-mail: quanlingxu@163.com.

Received date: 2023-10-16

  Accepted date: 2024-01-26

  Online published: 2024-04-28

Fold

Abstract

Polymyositis/dermatomyositis (PM/DM) is a heterogeneous autoimmune disease characterized by inflammatory cell infiltration in skeletal muscles with unknown etiology. The incidence of interstitial lung disease (ILD) in PM/DM is higher. ILD is the most important factor affecting its prognosis. Existing evidence suggests that there is significant heterogeneity in PM/DM-related ILD, which requires individualized treatment based on the onset form, progression rate, lesion involvement range, laboratory examination, presence of adverse prognostic factors, and response to treatment of ILD. This article summarizes the research progress in the treatment of PM/DM-related ILD in recent years, including the selection of traditional therapeutic drugs, timing of medication, and new drugs attempted in this field in clinical practice (such as biological agents and Janus kinase inhibitors), intravenous immunoglobulin, anti-fibrotic drugs, and potentially effective non-drug treatment methods, aiming at providing reference for clinical doctors to formulate PM/DM-ILD treatment plans and improve patient prognosis.

Key words： polymyositis; dermatomyositis; interstitial lung disease; medication

Cite this article

ZHENG Xiaofeng , XU Ling . Research progress in the treatment of interstitial lung disease related to polymyositis/dermatomyositis[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(4) : 531 -536 . DOI: 10.3969/j.issn.1674-8115.2024.04.015

References

1 SUN K Y, FAN Y, WANG Y X, et al. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020[J]. Semin Arthritis Rheum, 2021, 51(1): 175-191.
2 DE SOUZA F H C, DE ARAUJO D B, VILELA V S, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies[J].Adv Rheumatol,2019, 59(1): 6.
3 KOHSAKA H, MIMORI T, KANDA T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists[J].J Dermatol,2019, 46(1): e1-e18.
4 中国研究型医院学会呼吸病学专业委员会. 特发性炎性肌病相关间质性肺疾病诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2022, 45(7): 635-650.
4 Respiratory Council of Chinese Research Hospital Association.Chinese expert-based consensus statement on diagnosis and treatment of idiopathic inflammatory myopathy associated interstitial lung disease[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(7): 635-650.
5 BARBA T, FORT R, COTTIN V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis[J]. Autoimmun Rev, 2019, 18(2): 113-122.
6 HUAPAYA J A, SILHAN L, PINAL-FERNANDEZ I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease[J]. Chest, 2019, 156(5): 896-906.
7 CHEN Y, BAI Z, ZHANG Z, et al. The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: a retrospective and prospective study[J]. Front Immunol, 2022, 13: 978429.
8 FUJISAWA T, HOZUMI H, KAMIYA Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial[J]. Respirology, 2021, 26(4): 370-377.
9 HALLOWELL R W, DANOFF S K. Diagnosis and management of myositis-associated lung disease[J]. Chest, 2023, 163(6): 1476-1491.
10 GO D J, PARK J K, KANG E H, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease[J]. Rheumatol Int, 2016, 36(1): 125-131.
11 KAMEDA H, NAGASAWA H, OGAWA H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis[J]. J Rheumatol, 2005, 32(9): 1719-1726.
12 NAKASHIMA R, HOSONO Y, MIMORI T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease[J]. Lupus, 2016, 25(8): 925-933.
13 TSUJI H, NAKASHIMA R, HOSONO Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis[J]. Arthritis Rheumatol, 2020, 72(3): 488-498.
14 ODDIS C V, REED A M, AGGARWAL R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial[J]. Arthritis Rheum, 2013, 65(2): 314-324.
15 XU L, WANG F, LUO F. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis[J]. Front Pharmacol, 2022, 13: 1019915.
16 HE C, LI W, XIE Q, et al. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review[J]. Front Immunol, 2021, 12: 820163.
17 MAHER T M, TUDOR V A, SAUNDERS P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial[J]. Lancet Respir Med, 2023, 11(1): 45-54.
18 ZOU J, LI T, HUANG X, et al. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody[J]. Ann Rheum Dis, 2014, 73(8): 1591-1593.
19 HOLZER M T, NIES J F, OQUEKA T, et al. Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis[J]. Chest, 2023, 163(1): e1-e5.
20 ZHANG X, ZHOU S, WU C Y, et al. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis[J]. Rheumatology (Oxford), 2021, 60(7): e227-e228.
21 PAIK J J, LUBIN G, GROMATZKY A, et al. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review[J]. Clin Exp Rheumatol, 2023, 41(2): 348-358.
22 CHEN Z, WANG X, YE S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease[J]. N Engl J Med, 2019, 381(3): 291-293.
23 TAKANASHI S, KANEKO Y, TAKEUCHI T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review[J]. Mod Rheumatol, 2022, 32(1): 231-237.
24 KURASAWA K, ARAI S, NAMIKI Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2018, 57(12): 2114-2119.
25 FAN L, LYU W, LIU H, et al. A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus[J]. J Rheumatol, 2022, 49(12): 1356-1364.
26 AGGARWAL R, CHARLES-SCHOEMAN C, SCHESSL J, et al. Trial of intravenous immune globulin in dermatomyositis[J]. N Engl J Med, 2022, 387(14): 1264-1278.
27 AGGARWAL R, CHARLES-SCHOEMAN C, SCHESSL J, et al. Prospective, double-blind, randomized, placebo-controlled phase Ⅲ study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")[J]. Medicine (Baltimore), 2021, 100(1): e23677.
28 WANG L M, YANG Q H, ZHANG L, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis[J]. Rheumatology (Oxford), 2022, 61(9): 3704-3710.
29 LI T, GUO L, CHEN Z W, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis[J]. Sci Rep, 2016, 6: 33226.
30 WANG J, WANG X, QI X, et al. The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study[J]. Front Med (Lausanne), 2022, 9: 871861.
31 LIANG J, CAO H, YANG Y, et al. Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study[J]. Front Med (Lausanne), 2021, 8: 626953.
32 SHIRAKASHI M, NAKASHIMA R, TSUJI H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment[J]. Rheumatology (Oxford), 2020, 59(11): 3284-3292.
33 ABE Y, KUSAOI M, TADA K, et al. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy[J]. Rheumatology (Oxford), 2020, 59(4): 767-771.
34 KOMAI T, IWASAKI Y, TSUCHIDA Y, et al. Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis[J]. Scand J Rheumatol, 2023, 52(1): 77-83.
35 SASAKI N, NAKAGOME Y, KOJIMA A, et al. Early initiation of plasma exchange therapy for anti-MDA5+ dermatomyositis with refractory rapidly progressive interstitial lung disease[J]. Intern Med, 2024, 63(2): 213-219.
36 FURUSAWA H, SUGIURA M, MITAKA C, et al. Direct hemoperfusion with polymyxin B-immobilized fibre treatment for acute exacerbation of interstitial pneumonia[J]. Respirology, 2017, 22(7): 1357-1362.
37 ENOMOTO N, NAOI H, MOCHIZUKA Y, et al. Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases[J]. BMC Pulm Med, 2022, 22(1): 387.
38 KONDOH Y, MAKINO S, OGURA T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease[J]. Respir Investig, 2021, 59(6): 709-740.
39 SHIMOJIMA Y, ISHII W, MATSUDA M, et al. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis[J]. J Clin Rheumatol, 2017, 23(2): 87-93.
40 ROMERO-BUENO F, DIAZ DEL CAMPO P, TRALLERO-ARAGUáS E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J]. Semin Arthritis Rheum, 2020, 50(4): 776-790.
41 OLDROYD A G S, LILLEKER J B, AMIN T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy[J]. Rheumatology (Oxford), 2022, 61(5): 1760-1768.
42 JEE A S, SHEEHY R, HOPKINS P, et al. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand[J]. Respirology, 2021, 26(1): 23-51.
Options
Outlines

/

〈 〉